✦ LIBER ✦

Multiple system atrophy (MSA, PSP, CBD)

Publisher: John Wiley and Sons
Year: 1992
Tongue: English
Weight: 376 KB
Volume: 7
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.870070539

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neuroendocrine responses to levodopa in

Neuroendocrine responses to levodopa in multiple system atrophy (MSA)

✍ Jeffery Kimber; Laura Watson; Christopher J. Mathias 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 2 views

Urinary and erectile dysfunction in mult

Urinary and erectile dysfunction in multiple system atrophy (MSA)

✍ A.G. Papatsoris; S. Papapetropoulos; C. Singer; C. Deliveliotis 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

Progression of multiple system atrophy (

Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG)

✍ Felix Geser; Gregor K. Wenning; Klaus Seppi; Michaela Stampfer-Kountchev; Christ 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

## Abstract The disease‐specific Unified Multiple System Atrophy Rating Scale (UMSARS) has been developed recently and validated for assessing disease severity in multiple system atrophy (MSA). Here, we aimed at (1) assessing rates of disease progression in MSA and (2) validating UMSARS for sensiti

Pontine MRI hyperintensities (“the cross

Pontine MRI hyperintensities (“the cross sign”) are not pathognomonic for multiple system atrophy (MSA)

✍ K. Bürk; M. Skalej; J. Dichgans 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB

Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder characterised by progressive cerebellar ataxia, basal ganglia symptoms, and autonomic

Multiple system atrophy: An update

✍ Gregor K. Wenning; Felix Geser; Michaela Stampfer-Kountchev; François Tison 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder that usually manifests in the early sixth decade of life and progresses relentlessly with a mean survival of 9 years. Clinically, MSA is dominated by autonomic/urogenital failure, which may be associated with either levodopa (L-d

Survival in multiple system atrophy

✍ Anette Schrag; Gregor K. Wenning; Niall Quinn; Yoav Ben-Shlomo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

## Abstract We here report survival in patients with multiple system atrophy (MSA) in a large, prospectively studied group of patients with MSA. Eighty‐five of 100 patients were known to have died. Three patients were rediagnosed as having PD. Twenty‐four patients came to autopsy, which showed MSA